Safety and efficacy of radioimmunotherapy with 90Yttrium-rituximab in patients with relapsed CD20+ B cell lymphoma: A feasibility study

Journal of Cancer Science and Therapy

Volumn 4, Issue 12, 2012, Pages 394-400

  Vaes, M ^a   Bron, D ^a   Vugts, D J ^b   Paesmans, M ^a   Meuleman, N ^a   Ghanem, G ^a   Guiot, T ^a   Vanderlinden, B ^a   Thielemans, K ^c   van Dongen, G A M S ^b   Flamen, P ^a   Muylle, K ^a,c  

^a JULES BORDET INSTITUTE   (Belgium)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c FACULTY OF MEDICINE AND PHARMACY   (Belgium)

Author keywords

CD20+; Monoclonal antibody; Non Hodgkin's lymphoma; Radioimmunotherapy; RituximabYttrium 90

Indexed keywords

CD20 ANTIGEN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IBRITUMOMAB TIUXETAN; RITUXIMAB; YTTRIUM 90;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUGATE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PANCYTOPENIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY CONTROL; RADIOIMMUNOTHERAPY; REFRACTORY THROMBOCYTOPENIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84872401306     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000173     Document Type: Article

References (28)

1. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, et al. (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463.
2. Buchegger F, Antonescu C, Delaloye AB, Helg C, Kovacsovics T, et al. (2006) Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma. Br J Cancer 94: 1770-1776.
3. Witzig TE, Molina A, Gordon LI, Emmanouilides C, Schilder RJ, et al. (2007) Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109: 1804-1810.
4. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, et al. (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352: 441-449.
5. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, et al. (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24: 4143-4149.
6. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, et al. (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26: 5156-5164.
7. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, et al. (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26: 4579-4586.
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
9. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833.
10. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725-3732.
11. Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 24: 4418-4425.
12. Illidge T, Morschhauser F (2011) Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol 24: 279-293.
13. Ivanov A, Swann R, Illidge T (2008) New insights into the mechanisms of action of radioimmunotherapy in lymphoma. J Pharm Pharmacol 60: 987-998.
14. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, et al. (2005) (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 46: 1898-1906.
15. Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, et al. (2006) Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 33: 1337-1345.
16. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, et al. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586.
17. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, et al. (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 21: 1263-1270.
18. Hénon P, Sovalat H, Becker M, Arkam Y, Ojeda-Uribe M, et al. (1998) Primordial role of CD34+ 38- cells in early and late trilineage haemopoietic engraftmentafter autologous blood cell transplantation. Br J Haematol 103: 568-581.
19. Demirer T, Buckner CD, Bensinger WI (1996) Optimization of peripheral blood stem cell mobilization. Stem Cells 14: 106-116.
20. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, et al. (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25: 4285-4292.
21. Lillington DM, Micallef IN, Carpenter E, Neat MJ, Amess JA, et al. (2001) Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin's lymphoma. J Clin Oncol 19: 2472-2481.
22. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, et al. (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17: 3793-3803.
23. van Dongen GA, Vosjan MJ (2010) Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother Radiopharm 25: 375-385.
24. Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, et al. (2012) Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zribritumomab tiuxetan and PET. Eur J Nucl Med Mol Imaging 39: 512-520.
25. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, et al. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20: 3262-3269.
26. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, et al. (2004) Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 103: 4429-4431.
27. Leahy MF, Turner JH (2011) Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 117: 45-52.
28. Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, et al. (2006) Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 47: 629-636.